- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
Research at a glance
Top areas of exploration
- Parkinson Disease , 43 publications
- Supranuclear Palsy, Progressive , 18 publications
- Multiple System Atrophy , 14 publications
- Parkinsonian Disorders , 13 publications
Research activity
Focus
Dr. McFarland is a member of the Norman Fixel Institute for Neurological Diseases and the Center for Translational Research in Neurodegenerative Disease (CTRND), which aims to bring the bench research closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and on identifying novel biomarkers for early detection and tracking of disease and therapeutic development. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.
Active clinical trials
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 18 Years - 75 Years
- Sexes
- All
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease…
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 30 Years - N/A
- Sexes
- All
My publications
Filter publications
97 publications
2019
Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis.
Laboratory investigation; a journal of technical methods and pathology
•2019
Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism.
Human brain mapping
•2019
Recognizing and treating atypical Parkinson disorders.
Handbook of clinical neurology
•2019
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
The Lancet. Neurology
•2017
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.
Neurology
•